Publication | Closed Access

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

VaccinationVaccine SafetyVaccinologyViviane StudyPrecancerous LesionsPhase 3Human Papillomavirus VaccinesVaccine TestingGynecologyHuman Papillomavirus 16/18Vaccine EfficacyPublic HealthPolyvalent VaccineMedicineEpidemiologyWomen's Health